somavaratan (VRS-317) / Aravive, Sanofi 
Welcome,         Profile    Billing    Logout  
 13 Diseases   0 Trials   0 Trials   41 News 
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Trial completion date, Trial termination, Trial primary completion date:  Versartis Long-Term Safety Study of Somavaratan (clinicaltrials.gov) -  Mar 9, 2018   
    P2/3,  N=385, Terminated, 
    Trial completion date: Mar 2018 --> Nov 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Nov 2017; The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, IO biomarker:  A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency (clinicaltrials.gov) -  Mar 9, 2018   
    P3,  N=21, Terminated, 
    Active, not recruiting --> Terminated; The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved N=75 --> 21 | Trial completion date: Jan 2020 --> Nov 2017 | Recruiting --> Terminated | Trial primary completion date: Sep 2019 --> Nov 2017; The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Trial completion date, Trial termination, Trial primary completion date:  Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD) (clinicaltrials.gov) -  Mar 8, 2018   
    P2,  N=34, Terminated, 
    N=75 --> 21 | Trial completion date: Jan 2020 --> Nov 2017 | Recruiting --> Terminated | Trial primary completion date: Sep 2019 --> Nov 2017; The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved Trial completion date: Dec 2017 --> Nov 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Nov 2017; Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority.
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment closed, Trial initiation date, Trial primary completion date:  Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317) (clinicaltrials.gov) -  Nov 24, 2017   
    P2/3,  N=41, Active, not recruiting, 
    Trial completion date: Dec 2017 --> Nov 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Nov 2017; Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority. Recruiting --> Active, not recruiting | Initiation date: Mar 2015 --> Aug 2015 | Trial primary completion date: Jun 2017 --> Nov 2017
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment closed:  Versartis Long-Term Safety Study of Somavaratan (clinicaltrials.gov) -  Nov 8, 2017   
    P2/3,  N=300, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=250 --> 34 | Trial primary completion date: Dec 2019 --> Oct 2017 Recruiting --> Active, not recruiting
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Trial completion, Trial initiation date, Head-to-Head:  VELOCITY: Long-Acting Growth Hormone in Children Compared to Daily rhGH (clinicaltrials.gov) -  Oct 13, 2017   
    P3,  N=136, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Jan 2015 --> Aug 2015
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment change:  Versartis Long-Term Safety Study of Somavaratan (clinicaltrials.gov) -  Sep 27, 2016   
    P2/3,  N=300, Recruiting, 
    Active, not recruiting --> Completed N=250 --> 300
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment closed, Trial primary completion date, Head-to-Head:  VELOCITY: Long-Acting Growth Hormone in Children Compared to Daily rhGH (clinicaltrials.gov) -  Aug 12, 2016   
    P3,  N=136, Active, not recruiting, 
    N=250 --> 300 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Aug 2017
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Phase classification:  Versartis Trial in Children to Assess Long-Acting Growth Hormone (clinicaltrials.gov) -  Aug 10, 2016   
    P1b/2a,  N=64, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Aug 2017 Phase classification: P1/2 --> P1b/2a
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Trial completion, Enrollment change:  Versartis Trial in Children to Assess Long-Acting Growth Hormone (clinicaltrials.gov) -  Dec 10, 2014   
    P1/2,  N=64, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=48 --> 64
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment open:  Versartis Long-Term Safety Study of Somavaratan (clinicaltrials.gov) -  Mar 9, 2014   
    P2/3,  N=250, Recruiting, 
    Active, not recruiting --> Completed | N=48 --> 64 Not yet recruiting --> Recruiting
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Enrollment closed:  Versartis Trial in Children to Assess Long-Acting Growth Hormone (clinicaltrials.gov) -  Dec 15, 2013   
    P1/2,  N=48, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  somavaratan (VRS-317) / Aravive, Sanofi
    Trial completion:  VRS-317 in Adult Subjects With Growth Hormone Deficiency (clinicaltrials.gov) -  Jul 18, 2012   
    P1,  N=50, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed